SM 88

Drug Profile

SM 88

Alternative Names: SM-88

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Tyme Technologies
  • Class Small molecules
  • Mechanism of Action Free radical stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 05 Jan 2017 Phase-II clinical trials in Prostate cancer (Second-line therapy or greater) in USA (unspecified route)
  • 05 Jan 2017 Efficacy data from a proof-of-concept phase I trial in Cancer released by Tyme Technologies
  • 05 Jan 2017 Preliminary efficacy and adverse events data from a phase Ib/II trial in Prostate cancer released by Tyme Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top